|
|
|
| Inhibitory Effects of Cyclooxygenase-2 Inhibited by shRNA on the Growth and Angiogenesis of Human Liver Cancer Cell Subcutaneous Xenograft Tumors in Nude Mice |
| CHEN Guang-hui1, LIU Yu2, KONG Fei-fei1, QIU Xin-xin1, CHENG Feng1, KUANG Wen-bin1, LI Pu1, TU Zhi-guang1 |
1. Key Laboratory of Laboratory Medical Diagnostics of Ministry of Education, Faculty of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, China;
2. Clinical Laboratory Center, Chongqing Tumor Hospital, Chongqing 400030, China |
|
|
|
Abstract Objective: To investigate the inhibitory effects of recombinant interference plasmid pshRNA-COX-2 on the growth and angiogenesis of human liver cancer cell Hep3B subcutaneous xenograft tumors in nude mice. Methods: The COX-2 mRNA and protein expressions were measured by reverse transcription polymerase chain reaction (RT-PCR) and Western blot, the VEGF mRNA expression was detected by RT-PCR after Hep3B cells were transfected with plasmid pshRNA-COX-2 and selected. Selected Hep3B cells were transplanted into the subcutaneous tissue of nude mice. Xenograft tumor volume was measured every three days and growth curves of tumors were drawn. The mice were killed after four weeks. The expression of COX-2 protein and microvessel density (MVD) in xenograft tumors were observed by immunohistochemistry. Results: Compared to the Hep3B cells without transfected by plasmid pshRNA-COX-2, the inhibition rates of COX-2 mRNA and protein expressions were 65.3% and 52.8% respectively in the pshRNA-COX-2 group (P<0.05), the inhibition rate of VEGF mRNA expression was 56.5% in the pshRNA-COX-2 group (P<0.05). The tumor volume in the pshRNA-COX-2 group was apparently smaller than that of the pshRNA-HK group and the untreated group (P<0.01). The COX-2 score and MVD in the pshRNA-COX-2 group were significantly lower than that of the pshRNA-HK group and the untreated group (P<0.01). Conclusion: The plasmid pshRNA-COX-2 can significantly inhibit the growth and angiogenesis of human liver cancer cell Hep3B subcutaneous xenografts in nude mice through inhibiting COX-2 expression.
|
|
Received: 17 November 2010
Published: 01 April 2011
|
|
|
|
|
| [1] Bosch F X, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis, 1999, 19(3): 271-285.
[2] Thomas M B, Zhu A X. Hepatocellular carcinoma:the need for progress. J Clin Oncol, 2005, 23(13): 2892-2899.
[3] Cerveilo M, Foderaa D, Florena, et a1. Correlation between expression of cyelooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma:possible role in tumor promotion and angiogenesis. World J Gastroenterol, 2005, 11(30): 4638 -4643.
[4] Cervello M, Montalto G. Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol, 2006, 12(32): 5113-5121.
[5] Uefuji K, Ichikura T, Mochizuki H. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol, 2001, 76(1): 26-30.
[6] Zhang H, Sun X F. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer . Am J Gastroenterol, 2002, 97(4): 1037-1041.
[7] Parrett M L, Haltis R E, Joarder F S, et al. Cyclooxygenase-2 expression in human breast cancer . Int J Oncology, 1997, 10(7): 503-507.
[8] Dohmen K, Okabe H, Ishibashi H. Regression of hepatocellular carcinoma due to cyclooxygenase (COX)-2 inhibitor. Am J Gastroenterol, 2006, 101(10): 2437-2438.
[9] Strillaccit A, Griffoni C, Spisni E, et al. RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells . Briti J of Can, 2006, 94(9):1300-1310.
[10] Charames G S, Bapat B. Cyclooxygenese-2 knockdown by RNA interference in colon cancer . Int J Oncol, 2006, 28(2): 543-549.
[11] 杨义明,刘预,涂植光,等. 短发夹RNA抑制肝癌细胞HepG2 COX-2基因表达的探讨. 中国肿瘤临床, 2007, 34(10): 566-569. Yang Y M, Liu Y, Tu Z G, et al. Chinese Journal of Clinical Oncology, 2007, 34(10): 566-569.
[12] Soumaoro L T, Uetake H, Takagi Y, et a1. Coexpression of VEGF-C and COX-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum, 2006, 49(3): 392-398.
[13] von Rahden B H, Stein H J, Puhringer F, et a1. Coexpression of cyclooxygenases(COX-1, COX-2) and vascular endothelial growth factors(VEGF-A,VEGF-C) in esophageal adenocarcinoma. Cancer Res, 2005, 65(12): 5038-5044.
[14] Joo Y E, Rew J S, Seo Y H, et a1. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol, 2003, 37(1): 28-33.
[15] Timoshenko A V, Chakraborty C, Wagner G F, et al. Cox-2 mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Briti J Cancer 2006, 94(8): 1154-1163.
[16] Liu H, Yang Y, Xiao J, et al. COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer. Anat Rec, 2010, 293(11): 1838-1846.
[17] Kern M A, Schoneweiss M M, Sahi D, et al. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis,2004, 25(7): 1193-1199.
[18] Wang R, Wang X, Lin F, et al. shRNA-targeted Cyclooxygenase (COX)-2 inhibits proliferation, reduces invasion and enhances chemosensitivity in laryngeal carcinoma cells. Mol Cell Biochem, 2008, 317(1-2): 179-188.
[19] Narayanan B A, Narayanan N K, Davis L, et al. RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol Cancer Ther, 2006, 5(5): 1117-1125. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
